2026 Annual Report LTR Pharma Limited ASX:LTP Pioneering novel treatments for men’s health Heading Body Contents 04 From the Chair 07 LTR Pharma Limited 09 Our leadership team 10 FY26 ASX highlights 11 SPONTAN ® 12 ROXUS ® 13 OROFLOW ® 14 ...
Appendix 4E and Annual Report to Shareholders
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from LTR Pharma
- SPONTAN Real-World Study Reports 93% Response
- Quarterly Activities/Appendix 4C Cash Flow Report
- LTR Executes U.S. Commercial Agreement with Strive
- LTR Executes Definitive U.S. Commercial Agreement with Shed
- Response to ASX Aware Letter
Later from LTR Pharma
- Appendix 4G and Corporate Governance Statement
- FY26 Results Announcement
- LTR Expands Men's Health Portfolio with KYZATREX Pilot
- Investor Presentation
- Application for quotation of securities - LTP
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma